Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas

Table 2

Cytokines levels comparison between normal volunteers, before transplantation, and at day 15 after transplantation.

Cytokines	Normal	Pretransplant	Day 15 post transplant	𝑃-value  Normal versus Pretransplant	𝑃-value  Normal versus Day 15 post transplant	𝑃-value  Pre versus Day 15 post transplant
	Median (25th-75th quartiles)	Median (25th-75th quartiles)	Median (25th-75th quartiles)
IL-1b	3.59 (2.32–5.55)	4.72 (3.48–7.79)	2.99 (1.3–8.11)	.5	.8	.1
IL-1ra	120.12 (90.59–287.77)	356.56 (228.95–662.87)	283.33 (142.52–434.73)	<.0001	<.0001	.01
IL-2	0 (0–56.12)	4.24 (0–23.87)	0 (0–7.89)	.01	.7	<.0004
IL-4	3.09 (2.09–3.99)	3.95 (3.33–5.43)	2.12 (1.25–3.63)	.6	.7	.02
IL-5	0.92 (0.69–1.67)	2.82 (1.79–3.96)	4.3 (2.93–13.75)	<.0001	<.0001	.01
IL-6	0 (0–2.14)	11.78 (5.6–21.05)	24.48 (9.84–48.72)	<.0001	<.0001	.01
IL-7	24.64 (13.59–39.08)	21.99 (16.85–39.95)	15.66 (5.77–26.61)	.04	.007	.02
IL-8	2.57 (0.35–7.71)	30.89 (19.91–97.72)	36.67 (27.02–71.78)	<.0001	<.0001	.2
IL-9	4.09 (0–68.28)	40.18 (4.93–91.22)	27.58 (8.29–64)	.04	.04	.003
IL-10	1.97 (1.24–3.84)	4.91 (3.91–8.16)	8.94 (5.91–13.61)	.01	<.0001	<.002
IL-12p70	6.7 (2.52–16.35)	15.27 (7.29–29.68)	7.61 (4.45–12.93)	<.0006	.2	<.0004
IL-13	2.93 (1.33–4.17)	2.49 (1.71–5.26)	1.46 (0.56–2.31)	.02	.5	<.002
IL-15	0 (0–0)	8.75 (0.07–110.5)	76.5 (5.4–219.22)	<.0001	<.0001	<.0001
IL-17	10.62 (0–30.66)	18.43 (4.33–49.92)	7.08 (0–17.14)	.01	.2	<.0001
Eotaxin	49.39 (41.43–76.41)	68.18 (42.26–104.04)	73.76 (44.96–108.87)	.02	<.0001	.6
FGF	0 (0–0)	0 (0–84.64)	0 (0–13.07)	.7	.8	.7
G-CSF	989 (385–1243)	83.08 (60.01–124.8)	67.48 (45.74–93.55)	<.0001	<.0001	<.0001
GM-CSF	161.74 (32.26–1142.8)	80.99 (41.13–173.59)	63.75 (25.4–164.6)	.01	<.0001	<.002
IFN-G	142.49 (87.71–264.05)	125.06 (78.04–193.52)	65.65 (28.81–86.42)	.03	<.0009	<.0001
IP-10	245.22 (150.9–326.4)	915.6 (585.98–1783.83)	1440.53 (102.2–3067.40)	<.0001	<.0001	<.0001
MCP-1	41.3 (0–90.25)	86.34 (33.83–146.48)	120.43 (54.46–209.55)	.02	<.0001	.008
MIP-1a	7.4 (4.58–10.52)	12.9 (8.62–31.7)	8.56 (5.35–1363)	<.001	.7	<.001
MIP-1b	51.23 (21.15–106.98)	97.36 (57.01–256.38)	104.34 (63.59–179.76)	<.002	<.0001	.6
PDGF	1260.24 (805.22–2289.82)	2071.16 (1060.34–3485.72)	423.71 (112.94–697.84)	<.0001	<.0001	<.0001
RANTES	2650.98 (1584.55–4500)	2600 (2600–3000)	2302.37 (297.92–1072.83)	.7	.1	<.001
TNF-G	0.74 (0–188.99)	70.48 (52.82–132.48)	32.06 (23.37–82.85)	.02	.07	<.0001
VEGF	23.13 (12–55.42)	77.38 (28.42–104.34)	36.52 (10.28–91.85)	<.0007	<.002	<.0001

Interleukin (IL)-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, Eotaxin, fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-gamma (IFN-G), interferon-gamma-inducible protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory proteins 1a and 1b (MIP-1a and MIP-1b), platelet-derived growth factor (PDGF), RANTES, tumor-necrosis-factor-gamma (TNF-G), and vascular endothelial growth factor (VEGF).